Weekly Update: November 29 to December 03, 2021. The website analysis and mapping will be updated every two weeks starting December 2021.
8 new or updated vaccine observational studies with results are available on our website: see here
| Absalon-Aguilar A, J Gen Intern Med, 2021 NCT04367168 |
Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID). |
| Araujo CSR, medrxiv, 2021 |
A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE |
| Arruda E A G, medrxiv, 2021 |
Clinical Trial of Efficacy and Toxicity of Disoproxil Tenofovir Fumarate and Emtricitabine for Mild to Moderate SARS-CoV-2 Infections |
| Asadi M, Diabetes Metab Syndr, 2021 |
Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial. |
| Asgardoon M, ResearchSquare, 2021 |
Efficacy of Levamisole with Standard Care Treatment vs Standard Care in Clinical Presentations of Non-Hospitalized Patients with COVID-19: A Randomized Clinical Trial |
| Babalola O, ResearchSquare, 2021 |
A Randomized Controlled Trial of Ivermectin Monotherapy Versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in Covid-19 Patients in Nigeria |
| Bar KJ, J Clin Invest, 2021 |
A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. |
| Davoodi L, Int J Cardiol Heart Vasc, 2021 |
Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. |
| Faramarzi H, medrxiv, 2021 |
Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial |
| Fralick M, medrxiv, 2021 |
Prone positioning of patients with moderate hypoxia due to COVID-19: A multicenter pragmatic randomized trial |
| Haeberle H, medrxiv, 2021 |
Inhaled Prostacyclin Improves Oxygenation in Patients with COVID-19-induced Acute Respiratory Distress Syndrome |
| Holubar M, medrxiv, 2021 |
Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial |
| Huang L, medrxiv, 2021 |
Ultra-short-wave diathermy shortens the course of moderate and severe COVID-19: a randomized controlled trial |
| Isa F, medrxiv, 2021 |
Repeat Subcutaneous Administration of REGEN-COV(R) in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19 |
| Johansson PI, Am J Respir Crit Care Med, 2021 |
Prostacyclin in Mechanically Ventilated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized, Clinical Trial |
| Jordan S, Unpublished, 2021 |
Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19) |
| Marcos M, Thromb Haemost, 2021 |
Therapeutic vs. prophylactic bemiparin in hospitalized patients with non-severe COVID-19 (BEMICOP): an open-label, multicenter, randomized trial. |
| Mazeraud A, Lancet Respir. Med., 2021 |
Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial |
| Menichetti F , JAMA, 2021 |
Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial. |
| Morici N, merdrxiv, 2021 |
Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. vs 40 mg b.i.d. The X-COVID19 Randomized Clinical Trial |
| Nair PR, Respir Care, 2021 |
Comparison of High-Flow Nasal Cannula and Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure Due to Severe COVID-19 Pneumonia. |
| Oliynyk O, Life, 2021 |
Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy. |
| Panda PK, Clin Pharmacol, 2021 |
Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19. |
| Ravishankar R, SSRN, 2021 |
Phase III, Randomized, Double-Blind, Placebo Controlled Trial of Efficacy, Safety and Tolerability of Antiviral Drug Umifenovir vs Standard Care of Therapy in Non-Severe Covid-19 Patients |
| Roshon M, Infect Dis Ther, 2021 |
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of a Novel Inhaled Biologic Therapeutic in Adults with Respiratory Distress Secondary to COVID-19 Infection. |
| Sarhan RM, J Infect Public Health, 2021 |
Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients. |
| Seong S, ResearchSquare, 2021 |
A multicenter, randomized, double-blind, placebo-controlled phase ii trial of intravenous inflammasome inhibitor (NuSepin) for the treatment of COVID-19 patients |
| Shenoy S , medrxiv, 2021 |
Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. |
| Tornero C, medrxiv, 2021 |
Non-invasive Vagus Nerve Stimulation for Respiratory Symptoms of COVID-19: Results From a Randomized Controlled Trial (SAVIOR I) |
| Toroghi N, Pharmacol Rep, 2021 |
Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial |
| Zhuravel SV, EClinicalMedicine, 2021 |
Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial. |
These interventions were not prioritized but they might be included in the future. Details here